143 related articles for article (PubMed ID: 15602725)
21. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
22. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
[TBL] [Abstract][Full Text] [Related]
23. [Basic approaches to anti-HIV resistance].
Baba M
Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
[TBL] [Abstract][Full Text] [Related]
24. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
[TBL] [Abstract][Full Text] [Related]
25. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
26. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
Martinez-Cajas JL; Wainberg MA
Antiviral Res; 2007 Dec; 76(3):203-21. PubMed ID: 17673305
[TBL] [Abstract][Full Text] [Related]
27. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
Bessong PO
Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
[TBL] [Abstract][Full Text] [Related]
29. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
Nadembega WM; Giannella S; Simpore J; Ceccherini-Silberstein F; Pietra V; Bertoli A; Pignatelli S; Bellocchi MC; Nikiema JB; Cappelli G; Bere A; Colizzi V; Perno CP; Musumeci S
J Med Virol; 2006 Nov; 78(11):1385-91. PubMed ID: 16998878
[TBL] [Abstract][Full Text] [Related]
30. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
31. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
32. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
34. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile.
Ríos M; Delgado E; Pérez-Alvarez L; Fernández J; Gálvez P; de Parga EV; Yung V; Thomson MM; Nájera R
J Med Virol; 2007 Jun; 79(6):647-56. PubMed ID: 17457921
[TBL] [Abstract][Full Text] [Related]
35. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
[TBL] [Abstract][Full Text] [Related]
36. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
[TBL] [Abstract][Full Text] [Related]
37. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
[TBL] [Abstract][Full Text] [Related]
39. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
